Physician profile
Thomas C Moore
NPI 1780677666
$10,743.05
in general payments reported to CMS, 2019-2025
47 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,557 · 2020: $1,546 · 2021: $1,607 · 2022: $2,007 · 2023: $1,511 · 2024: $1,322 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,026.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,185.27 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,125.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,063.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,005.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $975.55 | 2021-2025 | |
| Pfizer INC. | $685.52 | 2019-2025 | |
| Novo Nordisk INC | $490.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $474.79 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $413.82 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $278.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Biohaven Pharmaceuticals, INC. | $271.56 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.73 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $215.84 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.74 | 2019-2025 | Jardiance, Ofev |
| Allergan, INC. | $163.38 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.